MX2017009122A - Inhalador de polvo seco con propionato de fluticasona y xinafoato de salmeterol. - Google Patents

Inhalador de polvo seco con propionato de fluticasona y xinafoato de salmeterol.

Info

Publication number
MX2017009122A
MX2017009122A MX2017009122A MX2017009122A MX2017009122A MX 2017009122 A MX2017009122 A MX 2017009122A MX 2017009122 A MX2017009122 A MX 2017009122A MX 2017009122 A MX2017009122 A MX 2017009122A MX 2017009122 A MX2017009122 A MX 2017009122A
Authority
MX
Mexico
Prior art keywords
fluticasone propionate
dry powder
dose
powder inhaler
patient
Prior art date
Application number
MX2017009122A
Other languages
English (en)
Inventor
Dalvi Mukul
Kee Tee Seah
Original Assignee
Teva Branded Pharmaceutical Products R&D Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55443303&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017009122(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Branded Pharmaceutical Products R&D Inc filed Critical Teva Branded Pharmaceutical Products R&D Inc
Publication of MX2017009122A publication Critical patent/MX2017009122A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0005—Details of inhalators; Constructional features thereof with means for agitating the medicament
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0005—Details of inhalators; Constructional features thereof with means for agitating the medicament
    • A61M15/0006—Details of inhalators; Constructional features thereof with means for agitating the medicament using rotating means
    • A61M15/0008—Details of inhalators; Constructional features thereof with means for agitating the medicament using rotating means rotating by airflow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0021—Mouthpieces therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Esta invención proporciona un inhalador de polvo seco que comprende: un medicamento en polvo seco que comprende propionato de fluticasona, xinafoato de salmeterol y un portador lactosa; en el que la dosis suministrada de propionato de fluticasona por activación es inferior a 100 µg; y en el que la dosis proporciona un FEV1, ajustado a los datos de base de un paciente, de más de 150 mL dentro de los 30 minutos de haber recibido la dosis. Un método de tratamiento a un paciente incluye administrar a un paciente un medicamento en polvo seco que tiene propionato de fluticasona, xinafoato de salmeterol y un portador lactosa; en el que la dosis suministrada de propionato de fluticasona por activación es inferior a 100 pg; y en el que la dosis proporciona un FEV1, ajustado a los datos de base de un paciente, de más de 150 mL dentro de los 30 minutos de recibir la dosis.
MX2017009122A 2015-01-20 2016-01-20 Inhalador de polvo seco con propionato de fluticasona y xinafoato de salmeterol. MX2017009122A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562105479P 2015-01-20 2015-01-20
PCT/US2016/014072 WO2016118589A1 (en) 2015-01-20 2016-01-20 Dry powder inhaler comprising fluticasone propionate and salmeterol xinafoat

Publications (1)

Publication Number Publication Date
MX2017009122A true MX2017009122A (es) 2017-10-12

Family

ID=55443303

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017009122A MX2017009122A (es) 2015-01-20 2016-01-20 Inhalador de polvo seco con propionato de fluticasona y xinafoato de salmeterol.
MX2021006751A MX2021006751A (es) 2015-01-20 2017-07-12 Inhalador de polvo seco con propionato de fluticasona y xinafoato de salmeterol.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021006751A MX2021006751A (es) 2015-01-20 2017-07-12 Inhalador de polvo seco con propionato de fluticasona y xinafoato de salmeterol.

Country Status (19)

Country Link
US (2) US9415008B2 (es)
EP (1) EP3247331A1 (es)
JP (1) JP2018503687A (es)
KR (1) KR20170103975A (es)
CN (1) CN107530357A (es)
AR (1) AR104771A1 (es)
AU (2) AU2016209363B2 (es)
BR (1) BR112017015353A2 (es)
CA (1) CA2974125A1 (es)
CL (1) CL2017001859A1 (es)
CO (1) CO2017008395A2 (es)
EA (1) EA201791632A1 (es)
HK (1) HK1245125A1 (es)
IL (1) IL253499A0 (es)
MA (1) MA41378A (es)
MX (2) MX2017009122A (es)
PE (1) PE20171258A1 (es)
TW (1) TW201628607A (es)
WO (1) WO2016118589A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015054124A2 (en) * 2013-10-07 2015-04-16 Teva Branded Pharmaceutical Products R&D, Inc. Dry powder inhaler
MA41378A (fr) * 2015-01-20 2017-11-28 Teva Branded Pharmaceutical Prod R & D Inc Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol
ES2884802T3 (es) 2016-11-18 2021-12-13 Norton Waterford Ltd Dispositivo de administración de fármacos con componentes electrónicos
CN110201280B (zh) * 2018-02-28 2021-07-30 张江 用于吸入给药装置的吸嘴和吸入给药装置
CN110201278B (zh) * 2018-02-28 2021-07-30 张江 用于吸入给药的药盒和吸入给药组合结构
CN110201281B (zh) * 2018-02-28 2021-08-06 张江 吸入给药装置和吸入给药组合结构
CN110064110A (zh) * 2019-05-29 2019-07-30 上海理工大学 一种容积旋钮式干粉储存吸入装置
GB2585206B (en) * 2019-07-01 2021-08-11 Merxin Ltd Portable inhaler

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270305A (en) * 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
PE20020163A1 (es) * 2000-06-23 2002-03-04 Norton Healthcare Ltd Sistema presurizado de receptaculo para inhalador de medicamento
PE20020067A1 (es) 2000-06-23 2002-02-05 Norton Healthcare Ltd Desaglomerador para inhalador de polvo seco accionado por la respiracion
PE20020387A1 (es) * 2000-08-31 2002-06-24 Glaxo Group Ltd Uso de una combinacion de salmeterol y fluticasona
EP1920763B2 (en) * 2000-11-30 2022-06-15 Vectura Limited Pharmaceutical compositions for inhalation
GB0124523D0 (en) 2001-10-12 2001-12-05 Glaxo Group Ltd Pharmaceutical combination
US20040105821A1 (en) 2002-09-30 2004-06-03 Howard Bernstein Sustained release pharmaceutical formulation for inhalation
US9114081B2 (en) * 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
RU2580315C3 (ru) * 2009-05-29 2021-06-18 Перл Терапьютикс, Инк. Композиции для респираторной доставки активных веществ и связанные с ними способы и системы
CN102573886A (zh) * 2009-09-17 2012-07-11 相互制药公司 用抗病毒剂治疗哮喘的方法
GB0919465D0 (en) * 2009-11-06 2009-12-23 Norton Healthcare Ltd Airflow adaptor for a breath-actuated dry powder inhaler
PL2436414T3 (pl) * 2010-05-18 2015-10-30 Ivax Pharmaceuticals Ireland Licznik dawek do inhalatorów i inhalator
US20130064870A1 (en) * 2010-05-20 2013-03-14 Sun Pharma Advanced Research Company Limited Dry powder inhalation composition
KR20130140358A (ko) * 2012-06-14 2013-12-24 한미약품 주식회사 살메테롤 지나포산염, 플루티카손 프로피오네이트 및 티오트로피움 브로마이드를 포함하는 흡입 제형용 건조 분말 및 이의 제조방법
JP2016523823A (ja) * 2013-04-29 2016-08-12 サノフィ・ソシエテ・アノニム 吸入可能な医薬組成物およびこれを含む吸入器デバイス
WO2015054124A2 (en) * 2013-10-07 2015-04-16 Teva Branded Pharmaceutical Products R&D, Inc. Dry powder inhaler
MA41378A (fr) * 2015-01-20 2017-11-28 Teva Branded Pharmaceutical Prod R & D Inc Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol

Also Published As

Publication number Publication date
CO2017008395A2 (es) 2018-01-05
EA201791632A1 (ru) 2017-12-29
US20180015035A1 (en) 2018-01-18
WO2016118589A1 (en) 2016-07-28
CN107530357A (zh) 2018-01-02
AU2016209363B2 (en) 2021-02-04
EP3247331A1 (en) 2017-11-29
BR112017015353A2 (pt) 2018-01-16
MX2021006751A (es) 2021-07-15
PE20171258A1 (es) 2017-08-28
JP2018503687A (ja) 2018-02-08
HK1245125A1 (zh) 2018-08-24
AR104771A1 (es) 2017-08-16
US9415008B2 (en) 2016-08-16
AU2016209363A1 (en) 2017-08-24
US20160206559A1 (en) 2016-07-21
AU2021202784A1 (en) 2021-05-27
CL2017001859A1 (es) 2018-04-06
IL253499A0 (en) 2017-09-28
MA41378A (fr) 2017-11-28
KR20170103975A (ko) 2017-09-13
TW201628607A (zh) 2016-08-16
CA2974125A1 (en) 2016-07-28

Similar Documents

Publication Publication Date Title
PH12016500619A1 (en) Dry powder inhaler
MX2021006751A (es) Inhalador de polvo seco con propionato de fluticasona y xinafoato de salmeterol.
MX2020001187A (es) Composiciones y métodos para la administración de virus adenoasociados.
MX2019011117A (es) Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
SA520411119B1 (ar) تركيبات جسيم شحمي تشمل عقاقير مكونة من حمض ضعيف واستخداماتها
MX2015001122A (es) Combinaciones farmaceuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf.
PH12014501560A1 (en) Carbamate compounds and of making and using same
MX2019012884A (es) Terapia de combinacion.
MX2014001050A (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero.
NZ707377A (en) Combination therapy methods for treating proliferative diseases
MX2019003685A (es) Composicion farmaceutica para uso en el tratamiento terapeutico del cancer y complicaciones del cancer.
WO2012040228A3 (en) Aerosol composition for administering drugs
MX2015015132A (es) Composiciones farmaceuticas inhalables y los dispositivos inhaladores que las contienen.
MX2015012315A (es) Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica.
WO2013104892A8 (en) Application of high dose compounds via inhalation
MX2021007177A (es) Formulacion de inhalacion de polvo seco y su uso para el tratamiento terapeutico de los pulmones.
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
ZA202002107B (en) Use of specific sirna against protein s for the treatment of hemophilia
MX2016008027A (es) Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington.
MX2015009891A (es) Composiciones farmaceuticas que comprenden particulas cristalinas de multicomponentes adecuadas para usar en terapia de inhalacion.
MX2015016418A (es) Dihidroetorfina para proporcionar el alivio del dolor y la anestesia.
MX2021011491A (es) Polvos secos inhalables.
MX2020007222A (es) Metodos para el tratamiento de afecciones inflamatorias de la piel.
MX2018005876A (es) Regimen de dosificacion de plasminogeno para la cicatrizacion de heridas.
TH173838A (th) เครื่องพ่นละอองยาผงแห้ง